17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Preterm Birth
Interventions
DRUG

17-alpha-hydroxyprogesterone caproate injectable

250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.

DRUG

Placebo

Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.

Trial Locations (18)

37403

Erlanger Medical Center, Chattanooga

50314

Mercy Medical Center, Des Moines

64111

Saint Luke's Hospital, Kansas City, Kansas City

75246

Baylor University Medical Center, Dallas

76104

Harris Methodist Fort Worth Hospital, Fort Worth

80110

Swedish Medical Center, Denver

80124

Skyridge Medical Center, Lonetree

80218

Presbyterian/St Luke's Hospital, Denver

80220

Rose Medical Center, Denver

85006

Banner Good Samaritan Hospital, Phoenix

85712

Tucson Medical Center, Tucson

92653

Saddleback Memorial Medical Center, Laguna Hills

92868

University of Southern California-Irvine Medical Center, Orange

95124

Good Samaritan Hospital, San Jose

98034

Evergreen Hospital, Kirkland

98405

Tacoma General Hospital, Tacoma

90801-1428

Long Beach Memorial Medical Center, Long Beach

98122-4307

Swedish Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Obstetrix Medical Group

INDUSTRY

NCT00163020 - 17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies | Biotech Hunter | Biotech Hunter